Journal of Hepatology
Volume 44, Issue 1 , Pages 27-32 , January 2006

Skin cancers after liver transplantation: What to do?

References 

  1. Euvrard S, Kanitakis J, Claudy A. Skin cancers in organ transplant recipients. N Engl J Med. 2003;348:1681–1691
  2. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc. 1993;25:1397–1399
  3. Sanchez E, Marubashi S, Jung G, Levy M, Goldstein R, Molmenti E, et al. De novo tumors after liver transplantation: a single institution experience. Liver Transpl. 2002;8:285–291
  4. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl. 2002;8:482–487
  5. Schmied E, Dufour JF, Euvrard S. Nontumoral dermatologic problems after liver transplantation. Liver Transpl. 2004;10:331–339
  6. Salard D, Parriaux N, Derancourt C, Aubin F, Bresson-Hadni S, Miguet J, et al. Manifestations dermatologiques chez les transplantés hépatiques. Etude épidémiologique et clinique chez 86 malades. Ann Dermatol Venereol. 2002;129:1134–1138
  7. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl. 2002;8:939–944
  8. Herrero JI, Espana A, Quijoga J, Sangro B, Pardo F, Alvarez-Cienfuegos J, et al. Non melanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005;11:1100–1106
  9. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein W, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or CsA-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer. 1997;80:1141–1150
  10. Haagsma EB, Hagens VE, Schaapveld M, van den Berg A, de Vries E, Klompmaker I, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34:84–91
  11. Bouwes-Bavinck JN, Hardie D, Green A, Vermeer B, Hardie I. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation. 1996;61:715–721
  12. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg. 1996;2:52–59
  13. Fung JJ, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001;7:S109–S118
  14. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl. 2001;7:971–975
  15. Frezza EE, Fung JJ, Van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997;44:1172–1181
  16. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsch G, Reyes J, et al. Comparative incidence of de novo non lymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation. 1998;66:1193–1200
  17. Euvrard S, Ulrich C, Lefrançois N. Immunosuppressants and skin cancer in transplant patients. Focus on Rapamycin. Dermatol Surg. 2004;30:628–633
  18. Guba M, Graeb C, Jauch KW, Geissler E. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77:1777–1782
  19. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dréno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623–628
  20. Mohamed MA, Robertson H, Booth TA, Balupuri S, Kirby J, Talbot D. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation. 2000;69:1002–1005
  21. Kreiss H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena F, et al. Long term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809–817
  22. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–1323
  23. Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35:193S–200S
  24. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squmaous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol. 2005;141:456–464
  25. Dragieva G, Hafner J, Dummer R, Schmid-Grendelmeier P, Roos M, Prinz BM, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77:115–121
  26. Kadry Z, Bronsther O, Van Thiel D, Randhawa P, Fung J, Starzl T. Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant. 1993;7:188–194
  27. Bismuth H, Samuel D, Venencie PY, Menouar G, Szekely A. Development of Kaposi's sarcoma in liver transplant recipients: characteristics, management and outcome. Transplant Proc. 1991;23:1438–1439
  28. Farge D. Kaposi's sarcoma in organ transplant recipients. Eur J Med. 1993;2:339–343
  29. Rezeig M, Fashir B, Hainau B, Al Ashgar H. Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation. 1997;63:1520–1521
  30. Besnard V, Euvrard S, Kanitakis J, Mion F, Boillot O, Faure M, et al. Kaposi's sarcoma after liver transplantation. Dermatology. 1996;193:100–104
  31. Andreoni M, Goletti D, Petrozzi P, Pozzetto A, Monini P, Sarmati L, et al. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. J Infect. 2001;43:195–199
  32. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation. 1997;64:669–673
  33. Garcia-Sesma A, Jimenez C, Loinaz C, Meneu J, Colina F, Marques E, et al. Kaposi's visceral sarcoma in liver transplant recipients. Transplant Proc. 2003;35:1898–1899
  34. Aseni P, Vertemati M, Minola E, Arcieri K, Bonacina E, Camozzi M, et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl. 2001;7:816–823
  35. Marcelin AG, Roque-Afonso AM, Hurtova M, Dupin N, Tulliez M, Sebagh M, et al. Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver transplant recipients. Liver Transpl. 2004;10:295–300
  36. Francès C, Mouquet C, Marcelin AG, Barete S, Agher R, Charron D, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation. 2000;69:1776–1779
  37. Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of Human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med. 1998;339:1358–1363
  38. Halmos O, Inturri P, Galligioni A, Di Landro D, Rigotti P, Tedeschi U, et al. Two cases of Kaposi's in renal and liver transplant recipients treated with interferon. Clin Transplant. 1996;10:374–378
  39. Pozo F, Tenorio A, de la Mata M, de Ory F, Torre-Cisneros J. Persistent Human Herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation. 2000;70:395–397
  40. Morris-Stiff G, Steel A, Savage P, Devlin J, Griffiths D, Portman B, et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant. 2004;4:444–446

PII: S0168-8278(05)00676-8

doi: 10.1016/j.jhep.2005.10.010

Journal of Hepatology
Volume 44, Issue 1 , Pages 27-32 , January 2006

Article Tools

* Image Usage & Resolution